Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Scil Proteins acquires Tat Phage display from ipal GmbH and Charité, Berlin
Deal enhances Scil Proteins’ Affilin discovery engine


Halle, Germany, September 14, 2008 – Scil Proteins today announced the signing of an agreement with ipal GmbH and Charité University Hospital, Berlin for the purchase of the Tat Phage display technique. Tat Phage display allows the precise selection of Affilin® therapeutics with high affinity and selectivity for disease targets from Scil Proteins’ proprietary Affilin® libraries. Financial terms were not disclosed.

Until now, Scil Proteins’ screening process was based on the Ribosome Display technology, accessed in 2006 in a cross-licensing deal with CAT/MedImmune. The combination of Tat Phage display with Ribosome Display enhances both the speed and reliability of the screening process.

“We are delighted to have secured exclusive rights to the use of these unique state of the art screening and selection techniques,” commented Dr. Ulrike Fiedler, CEO of Scil Proteins. “This further strengthens our competitive position for the Affilin® therapeutics platform.”

Dr. Arnd Steuernagel, CSO, added, “Tat Phage display will significantly expand the range of applicable selection criteria available for an Affilin® selection campaign. In combination with our fully automated screening process, Affilin® identification will become more flexible with regard to different target classes.”

Scil Proteins will use this combined screening capability to identify Affilin® lead therapeutic candidates in the core indications of cancer and inflammation/infectious diseases.

About Scil Proteins

Scil Proteins specializes in research, development and production of recombinant proteins. Scil Proteins is actively involved in two business areas: (1) Scil Proteins Pharma discovers and develops innovative bio-pharmaceutical products on the basis of the Affilin® technology, and (2) Scil Proteins Production produces recombinant proteins as a contract manufacturing organization for research, clinical studies and market. To learn more about Scil Proteins please visit www.scilproteins.com

About ipal

ipal GmbH (innovations, patents, licences) is financed by the Berlin universities FU, HU, TU, FHTW and TFH as well as the Investitionsbank Berlin (IBB). The patent exploitation agency assesses and markets the inventions of university scientists and academics on an exclusive basis. Based on cooperation treaties ipal works in the field of biotechnology for its strong Berlin partners Charité-Universitätsmedizin, Robert-Koch-Institut, Deutsches Herzzentrum, as well as for the Paul-Ehrlich-Institut in Langen and the International University Bremen. ipal manages all services from the evaluation of patentable technologies to comprehensive patent protection and finally to the evaluation of market potential and commercialization of the invention.

Contact

Dr. Henning Afflerbach
CBO
Scil Proteins GmbH
t: +49 (0) 3 45 2799 63 65
e: henning.afflerbach@scilproteins.com

Dr. Douglas Pretsell
Senior Account Director
College Hill
t: +49 (0) 89 5700 1806
e: douglas.pretsell@collegehill.com

Marcel Tilmann
Project Manager Life Science
ipal GmbH
t: +49 (0) 30 2125 48 27
e: marcel.tilmann@ipal.de

Sabrina Gohlisch
Public Relations
ipal GmbH
t: +49 (0) 30 2125 48 30
e: sabrina.gohlisch@ipal.de

Notes for editors:

About Affilin® Therapeutics:

Scil Proteins Affilin® therapeutics platform has been designed for the rapid selection of novel pharmaceutical proteins with high specificity for disease relevant targets. Affilin® therapeutics are small, very stable and perfectly suited for penetration of diseased tissue and application in destabilizing milieu conditions. As such, Affilin® therapeutics enter indication areas where other more complex and less stable molecules remain ineffective.

Affilin® therapeutics are so called scaffold proteins derived from variations of the natural protein Ubiquitin, a protein with ubiquitous distribution pattern in the human body. Due to the high degree of sequence conservation of their scaffold Ubiquitin Affilin® therapeutics bear very low immunogenic potential and offer predictive immunogenicity screening in relevant animal models.

Scil Proteins proprietary Multi-Affilin® platform allows the precise modulation of pharmacokinetic parameters of Affilin® therapeutics resulting in serum half lives applicable for acute and chronic treatment settings. Scil Proteins Affilin® and Multi-Affilin® platforms are broadly patent protected for a comprehensive freedom to operate on multiple disease targets of choice.

About Tat Phage Display:

The Tat Phage Display technique uses the twin-arginine-translocase (Tat) pathway for protein transport across the cytoplasmic membrane. In contrast to ‘classical’ Phage Display, which uses the Sec-dependent transport system, the Tat translocation enables the transport of folded proteins in their native forms.


Publisher Contact Information:

Scil Proteins GmbH
+49 (0) 3 45 2799 63 65
henning.afflerbach@scilproteins.com

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.

Data


26,130
Tech investments
From our Online Data Service
16,883
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.